Mercy Bioanalytics, Inc

Mercy Bioanalytics, Inc., located in Waltham, MA, is at the forefront of cancer detection innovation, developing low-cost blood-based tests that utilize advanced qPCR technology and extracellular vesicles (EVs). With a focus on early-stage cancer detection, their proprietary Mercy Halo platform enables the identification of cancer-associated biomarkers, aiming to improve patient outcomes through accessible and accurate diagnostics.

The company's dedicated team, led by visionary co-founders and experienced professionals, is united in the mission to save lives by enhancing the effectiveness of cancer detection methods. By prioritizing rigorous scientific studies and leveraging the unique properties of exosomes, Mercy Bioanalytics is paving the way for breakthroughs in early cancer diagnosis, which have historically been elusive due to the limitations of traditional cfDNA approaches.

Generated from the website